Recent CRSP News
- CRISPR Therapeutics Proposes New Appointment to the Board of Directors • GlobeNewswire Inc. • 03/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:45:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 10:45:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/21/2024 12:50:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 12:45:22 PM
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 02/21/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:45:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/15/2024 09:30:50 PM
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit • GlobeNewswire Inc. • 02/15/2024 01:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/13/2024 01:44:31 PM
- CRISPR Therapeutics Announces $280 Million Registered Direct Offering • GlobeNewswire Inc. • 02/13/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 11:30:54 AM
- European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) • GlobeNewswire Inc. • 02/13/2024 07:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2024 10:45:05 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/29/2024 09:08:41 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/29/2024 09:00:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 10:45:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/16/2024 10:00:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:11:36 PM
- CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia • GlobeNewswire Inc. • 01/16/2024 09:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 04:36:20 PM
- CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:23:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 01:58:16 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM